Skip to main content

Table 3 Univariate analysis for association of baseline characteristics and therapeutic response with PFS and OS from start of PLD.

From: Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

Characteristics Number of patients Median PFS, months P value Median OS, months P value
All 129 5.8   14.2  
Age      
   < 63 64 5.7 0.147 12.5 0.776
   ≥63 64 7.3   14.6  
Age      
   < 50 17 4.0 0.247 16.6 0.880
   ≥50 112 6.0   14.2  
No. cardiac risk factors      
   1 - 2 88 5.3 0.997 14.5 0.163
   ≥3 41 6.4   11.1  
No. metastatic sites      
   1-3 99 7.1 0.021 15.3 < 0.001
   4-7 30 3.6   6.0  
Metastatic site      
   Visceral 92 5.4 0.034 12.5 0.618
   Nonvisceral 37 9.8   14.3  
Prior endocrine therapy      
   No 33 5.4 0.305 14.8 0.061
   Yes 96 6.0   12.4  
No. of prior chemos+      
   0 - 3 95 7.3 0.001 14.5 0.01
   ≥4 34 5.0   10.1  
Prior anthracycline      
   No 52 7.8 0.104 15.1 0.057
   Yes 77 5.7   10.1  
Prior taxane      
   No 56 7.8 0.036 14.3 0.392
   Yes 73 5.4   12.5  
Response      
   CR/PR 34 10.0 < 17.5 < 0.001
   SD 24 11.9 0.001 24.6  
   PD 62 2.8   8.6  
   NE 9 2.4   3.0  
PLD extension*      
   6 cycles, no extension 31 9.8 0.466 21.3 0.516
   > 6 cycles 17 10.9   24.2  
  1. *Patients who achieved SD, PR or CR after scheduled PLD (i.e., 6 cycles). +Adjuvant chemotherapy was counted as prior therapy line.